Private Market View

SHANMU Biotech

Shenzhen, China · Founded 2020 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
$2.8M
Last round

Key facts

  • It has raised $2.8M; the latest was Early Stage VC in Jun 2025.
  • Notable investors include Green Pine Capital Partners, QF Capital, Langke Investment, Beijing Qichen Investment Management, Glacier Capital China8 tracked in total.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 8 names
  • ·Watchlist + deal alerts for SHANMU Biotech
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for SHANMU Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About SHANMU Biotech

Developer of AI-powered micro medical robots designed for home health monitoring through digital microfluidic chipsets. The company's technologies include urine-based metabolic analysis and disease cycle management algorithms, enabling continuous health tracking and early detection of disease correlations for personalised, at-home care.

Sector
Healthcare
HQ
Shenzhen, China
Founded
2020
Employees
10
Ownership
Privately Held (backing)
PA Mark — not yet priced

SHANMU Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in SHANMU Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on SHANMU Biotech in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.